A phase I clinical study investigating the combination of fianlimab (an anti‐LAG‐3 antibody) and cemiplimab (an anti‐PD‐1 antibody) in advanced HNSCC patients revealed a satisfactory level of safety, tolerability, and efficacy [89]. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.